JP2024524301A - 活性化肝星細胞(hsc)の枯渇及びその使用 - Google Patents

活性化肝星細胞(hsc)の枯渇及びその使用 Download PDF

Info

Publication number
JP2024524301A
JP2024524301A JP2023579541A JP2023579541A JP2024524301A JP 2024524301 A JP2024524301 A JP 2024524301A JP 2023579541 A JP2023579541 A JP 2023579541A JP 2023579541 A JP2023579541 A JP 2023579541A JP 2024524301 A JP2024524301 A JP 2024524301A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
binding molecule
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524301A5 (cg-RX-API-DMAC7.html
Inventor
シャンヤン ルー、クリス
ジャスティン クー、シャン―ジュ
ミンファ チャン
チャン、ルイペン
Original Assignee
ラエクナ セラピューティクス シャンハイ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラエクナ セラピューティクス シャンハイ カンパニー リミテッド filed Critical ラエクナ セラピューティクス シャンハイ カンパニー リミテッド
Publication of JP2024524301A publication Critical patent/JP2024524301A/ja
Publication of JP2024524301A5 publication Critical patent/JP2024524301A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023579541A 2021-07-02 2022-06-30 活性化肝星細胞(hsc)の枯渇及びその使用 Pending JP2024524301A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021104201 2021-07-02
CNPCT/CN2021/104201 2021-07-02
PCT/CN2022/102692 WO2023274352A1 (en) 2021-07-02 2022-06-30 Depletion of activated hepatic stellate cells (hscs) and uses thereof

Publications (2)

Publication Number Publication Date
JP2024524301A true JP2024524301A (ja) 2024-07-05
JP2024524301A5 JP2024524301A5 (cg-RX-API-DMAC7.html) 2025-07-07

Family

ID=84691485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579541A Pending JP2024524301A (ja) 2021-07-02 2022-06-30 活性化肝星細胞(hsc)の枯渇及びその使用

Country Status (11)

Country Link
US (1) US20240254239A1 (cg-RX-API-DMAC7.html)
EP (1) EP4363443A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024524301A (cg-RX-API-DMAC7.html)
KR (1) KR20240070496A (cg-RX-API-DMAC7.html)
CN (2) CN119039440A (cg-RX-API-DMAC7.html)
AU (1) AU2022304943A1 (cg-RX-API-DMAC7.html)
CA (1) CA3222788A1 (cg-RX-API-DMAC7.html)
IL (1) IL309804A (cg-RX-API-DMAC7.html)
MX (1) MX2024000057A (cg-RX-API-DMAC7.html)
TW (1) TW202317632A (cg-RX-API-DMAC7.html)
WO (1) WO2023274352A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4076526A4 (en) 2019-12-17 2024-07-03 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof
CN116492463B (zh) * 2023-03-31 2023-11-17 珠海市人民医院 Cd155分子在肝纤维化领域中的应用
TW202513591A (zh) * 2023-08-01 2025-04-01 大陸商來凱醫藥科技(上海)有限公司 抗acvr2b抗體及其用途
CN119930817B (zh) * 2024-12-24 2025-12-02 国科大杭州高等研究院 Tigit全人源抗体及其制备方法与应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037029A1 (en) * 1996-03-22 1997-10-09 Protein Design Labs, Inc. MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR β RECEPTOR AND METHODS OF USE THEREOF
AU2011265460A1 (en) * 2003-01-09 2012-01-19 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2015501814A (ja) * 2011-12-05 2015-01-19 エックス−ボディ インコーポレイテッド Pdgf受容体ベータ結合ポリペプチド
CN104592395A (zh) * 2015-01-27 2015-05-06 中国药科大学 Vegfr2单链抗体与mica融合蛋白的制备方法及用途
JP2016504416A (ja) * 2013-01-09 2016-02-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 抗pdgfr−ベータ抗体及びそれらの使用
WO2016115953A1 (zh) * 2015-01-21 2016-07-28 中国药科大学 一种靶向vegfr2的抗体融合蛋白的制备及其用途
JP2021527086A (ja) * 2018-06-13 2021-10-11 シンガポール ヘルス サーヴィシーズ プライベート リミテッド Il−11ra抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2012261721A1 (en) * 2006-03-17 2013-01-10 Gilead Sciences, Inc. Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
US20140088019A1 (en) * 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
CA3007898A1 (en) * 2015-12-28 2017-07-06 Innate Pharma Variable regions for nkp46 binding proteins
KR102585976B1 (ko) * 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
US20200399376A1 (en) * 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN114126663A (zh) * 2019-05-16 2022-03-01 沙塔克实验室有限公司 Nk细胞定向的嵌合蛋白

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037029A1 (en) * 1996-03-22 1997-10-09 Protein Design Labs, Inc. MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR β RECEPTOR AND METHODS OF USE THEREOF
AU2011265460A1 (en) * 2003-01-09 2012-01-19 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2015501814A (ja) * 2011-12-05 2015-01-19 エックス−ボディ インコーポレイテッド Pdgf受容体ベータ結合ポリペプチド
JP2016504416A (ja) * 2013-01-09 2016-02-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 抗pdgfr−ベータ抗体及びそれらの使用
WO2016115953A1 (zh) * 2015-01-21 2016-07-28 中国药科大学 一种靶向vegfr2的抗体融合蛋白的制备及其用途
CN104592395A (zh) * 2015-01-27 2015-05-06 中国药科大学 Vegfr2单链抗体与mica融合蛋白的制备方法及用途
JP2021527086A (ja) * 2018-06-13 2021-10-11 シンガポール ヘルス サーヴィシーズ プライベート リミテッド Il−11ra抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Afuco(TM) Anti-PDGFRB Recombinant Antibody (AFC-TAB-448CQ), ADCC Enhanced", CREATIVE BIOLABS [ONLINE], JPN6026018498, 1 January 2021 (2021-01-01), ISSN: 0005853679 *
RUI LI ET AL., APOPTOSIS, vol. 25, JPN6026018499, 2020, pages 105 - 119, ISSN: 0005853680 *

Also Published As

Publication number Publication date
CA3222788A1 (en) 2023-01-05
EP4363443A4 (en) 2025-08-06
KR20240070496A (ko) 2024-05-21
CN117980328A (zh) 2024-05-03
CN119039440A (zh) 2024-11-29
IL309804A (en) 2024-02-01
AU2022304943A1 (en) 2024-01-18
MX2024000057A (es) 2024-04-02
US20240254239A1 (en) 2024-08-01
EP4363443A1 (en) 2024-05-08
TW202317632A (zh) 2023-05-01
WO2023274352A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
WO2023274352A1 (en) Depletion of activated hepatic stellate cells (hscs) and uses thereof
US20260027209A1 (en) Claudin-6 binding moieties and uses thereof
WO2023030503A1 (en) Anti-acvr2a antibodies and uses thereof
WO2021170100A1 (en) Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof
US20240059794A1 (en) Gucy2c binding molecules and uses thereof
WO2024041650A1 (en) Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
WO2025140212A1 (en) Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
WO2025067338A1 (en) Dll3 binding moieties and uses thereof
JP2023546765A (ja) Cd20結合分子及びその使用
US20260091061A1 (en) Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
TW202337904A (zh) IL-1β結合蛋白之材料及方法
CA3211501A1 (en) Materials and methods for targeting regulatory t cells for enhancing immune surveillance
WO2024160261A1 (en) Anti-lilrb1 and/or anti-lilrb2 antibodies and uses thereof
HK40114909A (en) Depletion of activated hepatic stellate cells (hscs) and uses thereof
HK40108252A (en) Depletion of activated hepatic stellate cells (hscs) and uses thereof
KR20260064755A (ko) 항-acvr2b 항체 및 이의 용도
EA049821B1 (ru) Связывающие gucy2c молекулы и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240313

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260807